Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relmacabtagene autoleucel as second-line treatment for adult relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
CTR20231934Phase 2Active
- Sponsor
- WuXi AppTec
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutein + zeaxanthin + omega-3 LCPUFA in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma (FL), sponsored by WuXi AppTec. Started Nov 2023; status: active.
02
Drugs
lutein + zeaxanthin + omega-3 LCPUFA
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20231934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231934.